Johnson & Johnson JNJ:NYSE

Earnings Announcement Next Earnings date is expected on 01/25/2022
Last Price$164.87NYSE Previous Close - Last Trade as of 7:00PM ET 1/21/22

Today's Change-0.38(0.23%)
Bid (Size)$164.45 (1)
Ask (Size)$165.00 (1)
Day Low / High$164.47 - 167.99
Volume10.6 M
 

View Pharmaceuticals: Major IndustryPeer Comparison as of 01/21/2022

 

Johnson & Johnson ( NYSE )

Price: $164.87
Change: -0.38 (0.23%)
Volume: 10.6 M
7:00PM ET 1/21/2022
 
 

Pfizer Inc ( NYSE )

Price: $52.79
Change: -1.26 (2.33%)
Volume: 41.1 M
7:00PM ET 1/21/2022
 
 

Abbvie Inc ( NYSE )

Price: $131.98
Change: -1.05 (0.79%)
Volume: 7.6 M
6:30PM ET 1/21/2022
 
 

Eli Lilly and Co ( NYSE )

Price: $243.06
Change: -0.07 (0.03%)
Volume: 2.8 M
7:00PM ET 1/21/2022
 
 

Merck & Co Inc ( NYSE )

Price: $79.98
Change: -0.77 (0.95%)
Volume: 18.5 M
7:00PM ET 1/21/2022
 

Read more news Recent News

Johnson & Johnson's COVID-19 Vaccine Fact Sheet Updated to Include Risk of Rare Bleeding Disorder
12:07PM ET 1/12/2022 MT Newswires

The US Food and Drug Administration on Tuesday updated the fact sheet for Johnson & Johnson's (JNJ) COVID-19 vaccine to include the risk of immune...

Georgia Enters $26 Billion Multi-State Opioid Litigation Settlement With Johnson & Johnson, Drug Distributors
10:38AM ET 1/07/2022 MT Newswires

Georgia state has joined the $26 billion multi-state settlement for lawsuits against Johnson & Johnson (JNJ) and three drug distributors for their alleged...

Johnson & Johnson COVID-19 Vaccine Offers Durable Protection, Study Shows
5:06PM ET 1/06/2022 MT Newswires

Johnson & Johnson (JNJ) said late Thursday new study results showed its single-shot COVID-19 vaccine provides durable protection against COVID-19...

Genocea Biosciences Teams Up with Janssen to Explore Immunogenicity of Neoantigens
3:02PM ET 1/04/2022 MT Newswires

Genocea Biosciences (GNCA), a firm developing neoantigen immunotherapies, unveiled a research and development collaboration and option agreement with...

Company Profile

Business DescriptionJohnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas, such as immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular & metabolic diseases. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular & neurovascular, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ. View company web site for more details
AddressOne Johnson & Johnson Plaza
New Brunswick, New Jersey 08933
Phone+1.732.524.0400
Number of Employees135,100
Recent SEC Filing01/20/202225-NSE
Chief Executive Officer & DirectorJoaquin Duato
Chief Financial Officer & Executive Vice PresidentJoseph J. Wolk
Global Chief Information Officer & Executive VPJames D. Swanson
Executive Vice President & General CounselMichael H. Ullmann

Company Highlights

Price Open$166.19
Previous Close$165.25
52 Week Range$151.47 - 179.92
Market Capitalization$434.0 B
Shares Outstanding2.6 B
SectorHealth Technology
IndustryPharmaceuticals: Major
Current Dividend / Yield$1.06 / 2.57%
Dividend Ex-Date02/18/2022
Dividend Pay-Date03/08/2022
Dividend Yield 5 Year Average2.56%
Next Earnings Announcement01/25/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings24.64
Earnings per Share$8.28
Beta vs. S&P 500N/A
Revenue$81.5 B
Net Profit Margin19.56%
Return on Equity26.59%

Analyst Ratings as of 12/16/2021

Buy
7
Overweight
3
Hold
10
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset